| Population 2012
|
21 million
|
| |
| | |
| Estimates of TB burden * 2012
|
Number (thousands)
|
Rate
(per 100 000 population)
|
| Mortality (excludes HIV+TB)
|
8.7
|
(3.9–15)
|
42
|
(19–73)
|
| Mortality (HIV+TB only)
|
1.3
|
(1.1–1.4)
|
6.1
|
(5.4–7)
|
| Prevalence (includes HIV+TB)
|
99
|
(48–170)
|
474
|
(230–804)
|
| Incidence (includes HIV+TB)
|
66
|
(55–77)
|
316
|
(266–369)
|
| Incidence (HIV+TB only)
|
5.5
|
(4.7–6.5)
|
27
|
(22–31)
|
| Case detection, all forms (%)
|
79
|
(67–94)
|
|
|
| |
| | |
| TB case notifications 2012
|
|
|
|
|
| New cases
|
|
(%)
|
Retreatment cases
|
(%)
|
| Smear-positive
|
21 124
|
(43)
|
Relapse
|
2 863
|
(64)
|
| Smear-negative
|
21 226
|
(43)
|
Treatment after failure
|
635
|
(14)
|
| Smear-unknown / not done
|
1 830
|
(4)
|
Treatment after default
|
972
|
(22)
|
| Extrapulmonary
|
4 776
|
(10)
|
Other
|
|
|
| Other
|
0
|
(0)
|
|
|
|
| Total new
|
48 956
|
|
Total retreatment
|
4 470
|
|
|
|
|
|
|
|
|
| Other (history unknown)
|
|
|
|
|
|
| Total new and relapse
|
51 819
|
|
Total cases notified
|
53 426
|
|
| |
| | |
| New cases
|
Smear-positive
|
Smear-negative/ unknown/
not done
|
Extrapulmonary
|
| M:F ratio
|
1.3
|
|
|
| Age < 15
|
982
|
|
2 080
|
| | |
| | |
| Laboratories
|
2012
|
| Smear (per 100 000 population)
|
0.6
|
| Culture (per 5 million population)
|
0.5
|
| Drug susceptibility testing (per 5 million population)
|
0.5
|
| Is second-line drug susceptibility testing available?
|
Yes, in country
|
| |
| | |
| Treatment success rate 2011 (%)
|
|
|
|
|
| New smear-positive and/or culture-positive
|
55
|
|
Is rifampicin used
throughout treatment for
new patients?
|
No
|
| New smear-negative/extrapulmonary
|
0
|
|
| Retreatment
|
0
|
|
| |
| | |
| TB/HIV 2012
|
Number
|
(%)
|
| TB patients with known HIV status
|
12 022
|
(23)
|
| HIV-positive TB patients
|
1 149
|
(10)
|
| HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)
|
1 149
|
(100)
|
| HIV-positive TB patients on antiretroviral therapy (ART)
|
1 149
|
(100)
|
| HIV-positive people screened for TB
|
11 703
|
|
| HIV-positive people provided with IPT
|
1 100
|
|
| | |
| | |
| Estimates of MDR-TB burden 2012*
|
|
New
|
|
Retreatment
|
| % of TB cases with MDR-TB
|
1.8
|
(0.1–3.4)
|
19
|
(7.4–31)
|
MDR-TB cases among notified pulmonary
TB cases
|
800
|
(44–1 500)
|
860
|
(330–1 400)
|
| |
| | |
| Reported cases of MDR-TB 2012
|
New
|
Retreatment
|
Total
|
| Cases tested for MDR-TB
|
|
45 (1%)
|
45
|
| Laboratory-confirmed MDR-TB cases
|
|
45
|
45
|
| Patients started on MDR-TB treatment
|
|
|
45
|
| |
| | |
| Financing TB control
|
2013
|
| National TB programme budget (US$ millions)
|
|
| % Funded domestically
|
|
| % Funded internationally
|
|
| % Unfunded
|
|
| |
| | |